Abstract
Background: CLL is a heterogeneous disease and prognosis is driven by different clinical and biological factors. The IGVH mutational status and the presence of cytogenetic abnormalities are the strongest predictors of outcome. Mutated IGVH and deletion 13q independently confer a survival advantage in CLL patients with better overall (OS) and progression-free survival (PFS). However, there is limited data on the outcome of patients harboring favorable deletion 13q and the unfavorable unmutated IGVH. The aim of the study is to assess the impact of the IGVH mutational status in patients with 13q deletion as a single mutation in CLL patients.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call